-
Cephalon Inc. v. Wockhardt Bio Ltd. et al DC CAFC
- 1:14-cv-01332
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 10/21/2014
- Closed: 05/18/2015
- Latest Docket Entry: 05/18/2015
- PACER
- Docket updated daily
1
Plaintiff
3
Defendants
1
Accused
Product
4
Patents-in-Suit
210
Days in
Litigation
-
Cephalon Inc. v. Wockhardt Bio Ltd. et al DC CAFC
- 1:14-cv-01332
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 10/21/2014
- Closed: 05/18/2015
- Latest Docket Entry: 05/18/2015
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Wockhardt Bio AG
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,436,190 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,445,524 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,609,863 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,791,270 B2 | All Asserted Claims |
Infringement
Entry 16
|
Wockhardt Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,436,190 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,445,524 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,609,863 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,791,270 B2 | All Asserted Claims |
Infringement
Entry 16
|
Wockhardt USA LLC
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,436,190 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,445,524 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,609,863 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,791,270 B2 | All Asserted Claims |
Infringement
Entry 16
|
